EARNEST Partners’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $254M | Buy |
1,120,011
+148,645
| +15% | +$26.5M | 0.92% | 22 |
|
|
2026
Q1 | $168M | Sell |
971,366
-16,893
| -2% | -$3.13M | 0.69% | 46 |
|
|
2025
Q4 | $197M | Sell |
988,259
-18,465
| -2% | -$3.35M | 0.84% | 28 |
|
|
2025
Q3 | $158M | Buy |
1,006,724
+8,467
| +0.8% | +$1.34M | 0.68% | 45 |
|
|
2025
Q2 | $151M | Sell |
998,257
-6,350
| -0.6% | -$847K | 0.68% | 45 |
|
|
2025
Q1 | $151M | Buy |
1,004,607
+22,453
| +2% | +$3.76M | 0.72% | 42 |
|
|
2024
Q4 | $181M | Buy |
982,154
+735
| +0.1% | +$142K | 0.81% | 34 |
|
|
2024
Q3 | $193M | Sell |
981,419
-23,067
| -2% | -$4.79M | 0.84% | 32 |
|
|
2024
Q2 | $208M | Buy |
1,004,486
+110,725
| +12% | +$25.1M | 0.97% | 23 |
|
|
2024
Q1 | $242M | Buy |
893,761
+4,393
| +0.5% | +$1.05M | 1.11% | 16 |
|
|
2023
Q4 | $210M | Buy |
889,368
+83,485
| +10% | +$16.4M | 1.05% | 18 |
|
|
2023
Q3 | $158M | Buy |
805,883
+41,689
| +5% | +$8.56M | 0.91% | 28 |
|
|
2023
Q2 | $161M | Buy |
764,194
+193,802
| +34% | +$38.6M | 0.9% | 29 |
|
|
2023
Q1 | $115M | Buy |
570,392
+91,806
| +19% | +$20.8M | 0.67% | 51 |
|
|
2022
Q4 | $104M | Buy |
478,586
+15,286
| +3% | +$3.34M | 0.64% | 61 |
|
|
2022
Q3 | $91.2M | Buy |
463,300
+288,052
| +164% | +$62.2M | 0.61% | 66 |
|
|
2022
Q2 | $37.5M | Sell |
175,248
-1,962
| -1% | -$479K | 0.25% | 128 |
|
|
2022
Q1 | $50.3M | Sell |
177,210
-603
| -0.3% | -$186K | 0.3% | 116 |
|
|
2021
Q4 | $67M | Sell |
177,813
-9,097
| -5% | -$3.53M | 0.39% | 102 |
|
|
2021
Q3 | $77.1M | Sell |
186,910
-23,660
| -11% | -$9.83M | 0.47% | 84 |
|
|
2021
Q2 | $77.9M | Sell |
210,570
-9,481
| -4% | -$3.17M | 0.46% | 87 |
|
|
2021
Q1 | $63.8M | Sell |
220,051
-46,058
| -17% | -$12.8M | 0.38% | 102 |
|
|
2020
Q4 | $66.5M | Sell |
266,109
-11,306
| -4% | -$2.69M | 0.46% | 90 |
|
|
2020
Q3 | $62.8M | Sell |
277,415
-50,840
| -15% | -$10.6M | 0.54% | 84 |
|
|
2020
Q2 | $57.2M | Buy |
328,255
+508
| +0.2% | +$81.1K | 0.54% | 83 |
|
|
2020
Q1 | $41.4M | Buy |
327,747
+54,577
| +20% | +$8.19M | 0.47% | 88 |
|
|
2019
Q4 | $41.7M | Buy |
273,170
+32,138
| +13% | +$4.45M | 0.33% | 106 |
|
|
2019
Q3 | $31.9M | Buy |
241,032
+304
| +0.1% | +$40.8K | 0.29% | 112 |
|
|
2019
Q2 | $34.2M | Sell |
240,728
-114
| -0% | -$15.5K | 0.31% | 109 |
|
|
2019
Q1 | $35M | Buy |
240,842
+667
| +0.3% | +$87.6K | 0.33% | 104 |
|
|
2018
Q4 | $27.2M | Sell |
240,175
-1,273
| -0.5% | -$159K | 0.3% | 110 |
|
|
2018
Q3 | $32.5M | Sell |
241,448
-5,489
| -2% | -$677K | 0.29% | 114 |
|
|
2018
Q2 | $27.7M | Sell |
246,937
-3,752
| -1% | -$406K | 0.26% | 119 |
|
|
2018
Q1 | $26.8M | Buy |
250,689
+8,114
| +3% | +$875K | 0.25% | 118 |
|
|
2017
Q4 | $26.6M | Sell |
242,575
-19,687
| -8% | -$2.14M | 0.25% | 114 |
|
|
2017
Q3 | $28.3M | Buy |
262,262
+20,683
| +9% | +$2.12M | 0.28% | 107 |
|
|
2017
Q2 | $24.4M | Buy |
241,579
+19,555
| +9% | +$1.8M | 0.26% | 112 |
|
|
2017
Q1 | $20M | Buy |
222,024
+222,020
| +5,550,500% | +$18.9M | 0.21% | 132 |
|
|
2016
Q4 | $0 | Buy |
+4
| New | +$304 | ﹤0.01% | 1152 |
|
Other funds holding CRL
AI
EARNEST Partners's CRL Position: Q2 2026 in Review
EARNEST Partners increased its Charles River Laboratories (CRL) stake by 15% in Q2 2026, buying an estimated $26.5M and bringing the position to 1,120,011 shares worth $254M. The position accounts for 0.92% of the portfolio, ranked #22.
EARNEST Partners first reported a position in CRL in Q4 2016 and has held it in 39 quarters since. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- EARNEST Partners held 1,120,011 shares of Charles River Laboratories worth $254M as of Q2 2026.
- EARNEST Partners bought 148,645 Charles River Laboratories shares in Q2 2026, an estimated $26.5M.
- Charles River Laboratories made up 0.92% of EARNEST Partners's portfolio in Q2 2026, its #22 holding.
- EARNEST Partners first reported a position in Charles River Laboratories in Q4 2016 and has held it in 39 quarters since.
- 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on EARNEST Partners's 13F filing for Q2 2026, filed 13 Aug 2026.